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1. Introduction
It was not until the discovery of the gene encoding
the amyloid precursor protein (APP) in the late
eighties that scientists became able to develop in vi-
tro model systems to study Alzheimer’s disease (AD).
Since then, few other proteins have attracted as
much scienti¢c attention as the ‘Alzheimer’s disease
proteins’. APP and the presenilins play key roles in
the early pathogenesis of the disease. APP is the
precursor protein of the amyloid peptides that pre-
cipitate in the amyloid plaques. The presenilins on
the other hand are closely associated with (if not
identical to) Q-secretase, the enzyme responsible for
the ¢nal release of amyloid peptides. The hypothesis
that merely a subtle change in this proteolytic step
leads to such a dramatic disease forced scientists to
focus on this molecular process. To analyze the intra-
cellular mechanisms that are at the basis of aberrant
amyloid production, it is important to develop ap-
propriate cellular models that mimic the in vivo sit-
uation. This chapter will focus on the importance
and relevance of speci¢c neuronal cell systems to
study the cell biology of AD-linked proteins.
2. Available models: from cell culture to transgenic
animal models
One of the major challenges in approaching the
pathogenesis of AD is the development of reliable
cellular as well as animal models that mimic de¢ned
molecular steps or aspects of the phenotype of the
human disease, respectively. The lack of naturally
occurring animal models developing AD or molecu-
lar links to the pathogenesis of sporadic AD were
initially a problem in AD research. However, rare
familial forms of the disease are caused by mutations
in three genes, encoding APP or presenilin 1 (PS1) or
2 (PS2). In addition, ApoE4 is known as a risk factor
[1^3]. Once disease-causing genes are identi¢ed, they
can be used by molecular and cell biologists to estab-
lish model systems. The discovery that missense mu-
tations in the APP gene coseggregates with the dis-
ease [4^7], triggered the interest to develop transgenic
mouse models [8,9]. However it took another four
years before the ¢rst APP transgenic mice strains
were published displaying convincing characteristics
of the disease [10^12]. The discovery of the presenilin
genes and AD causing mutations associated with
them [13,14] refueled this ¢eld and led to the estab-
lishment of new transgenic models [15^17] (reviewed
by D. Westaway).
Transgenic modeling has certainly many attractive
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advantages. It allows the study of characteristic fea-
tures of the pathogenesis in vivo, and it is obvious
that implications of the disease process at the phys-
iological and ^ important for AD ^ psychological
and behavioral level (especially at the initial steps
leading to the disease [18,19]) are best studied in
animal models. However it appears to be di⁄cult
to mimic the complete phenotype in mice since thus
far no transgenic line has been reported that displays
all pathological hallmarks at once, such as paired
helical ¢laments and tangles adjacent to plaques.
Although transgenic mice o¡er relevant AD mod-
els to study the production, secretion and deposition
of the di¡erent LA4 peptides with regard to missense
mutations in APP and/or presenilins, several other
cell biological aspects of these proteins cannot be
analyzed in great detail in animal models. For in-
stance, the complexity of the proteolytic processing
of APP, the modulation of speci¢c proteolytic steps
by the presenilins and, importantly, the subcellular
localization of these processes can be much better
studied in isolated neurons cultured in vitro. Many
advancements in the ¢eld have indeed been made by
studying AD proteins in cell cultures.
For instance, cell biological experiments have
learned how consecutive proteolytic cleavage of
APP by L-secretase and Q-secretase produces amyloid
peptides of mainly 40 and 42 amino acids long.
These peptides are the main constituents of amyloid
plaques in the brain. A third protease, called K-sec-
retase cleaves within the amyloid peptide sequence
thereby preventing peptide production [20]. All
known AD-causing mutations in the APP or in the
presenilin 1 or 2 genes cause an increased secretion of
the longer, more neurotoxic form of the amyloid
peptide [15^17,20,21]. Presenilin 1 de¢ciency inhibits
the Q-secretase activity resulting in a strong decrease
in the production of both amyloid peptides [22], an
e¡ect that can be mimicked by mutating either of the
two aspartic residues in transmembrane region 6 or 7
of presenilin 1 [23]. While the identity of the Q-secre-
tase remains unknown, strong candidates for both K-
and L-secretase have been recently obtained [24^28].
To explore further the intracellular functions and
properties of the AD-related gene products and
how and where the newly identi¢ed secretases inter-
fere with them, good cell models will remain indis-
pensable.
In Section 3 we will review the di¡erent non-neu-
ronal and neuronal cell models available and discuss
their applications in AD research. We will focus on a
particularly promising approach that combines trans-
gene technology and cell culture.
3. Non-neuronal versus neuronal cell cultures
AD is clearly a problem of the brain and genetic
studies combined with cell biological and neuropa-
thological studies have established a role for APP
and LA4 generation in the pathogenesis of AD.
Although both neurons and astrocytes produce
high levels of LA4 [29] and may each contribute to
the development of senile plaques, neuronal cells are
apparently most dramatically a¡ected by the disease.
Therefore, the study of neuronal cells seems to be
more relevant when trying to resolve the molecular
aspects of the pathological cascade leading to AD.
This idea is also supported by molecular evidence:
several results indicate that certain characteristics of
APP metabolism are neuron speci¢c. APP can be
processed by two alternative pathways, the L-secre-
tase pathway leading to the formation of amyloid
peptides and the K-secretase pathway clipping the
protein in the amyloid sequence thereby precluding
amyloid production. Neuronal and non-neuronal
cells essentially di¡er in the amplitude, magnitude
or importance of either pathway. Although constitu-
tive production of LA4 (i.e. the L-secretase pathway)
has been documented in a variety of untransfected
and APPwt transfected cell lines, the utilization of
this pathway is rather minor in non-neuronal cells
[30,31]. Instead the K-secretase processed products
^ like p3 ^ are recovered at much higher levels in
conditioned media of these cells. On the contrary,
in vitro studies demonstrated a limited use of the
K-secretase pathway in neuronal cells [32,33]. In-
stead, abundant LA4 production is observed in rat
hippocampal neurons transfected with human APP
[31]. Since the extraneuronal deposition of these
amyloid peptides in plaques is an invariable feature
of the disease and believed to be fundamental to the
disease process [34,35], these observations are of im-
portance. Neurons appear to also generate an intra-
cellular pool of amyloid peptides by a not well
understood mechanism [36]. Since several groups
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failed to detect intracellular LA4 in non-neuronal
cells [37^39] this mechanism could be neuron speci¢c.
In non-neuronal cells, amyloid peptides were only
detected at or close to the cell surface [40] suggesting
that newly generated peptide is immediately secreted
[41^43]. Interestingly, the Swedish double mutation,
which renders APP more sensitive to L-secretase
cleavage [44], makes APP to be processed via the
L-secretase pathways in non-neuronal HEK293 cells,
causing APP metabolism to be more similar to APP
metabolism in neurons such as human NT2N cells
[37,45]. Several studies have recently emphasized the
importance of the intracellular formation of amyloid
peptides. First, neuronal endocytic abnormalities like
enlarged endosomes, increased endosomal activity
and endosomal delivery of lysosomal proteases
were observed in sporadic AD and suggests a poten-
tial mechanism of accelerated L-amyloidogenesis [46].
Second, more than half of the total intracellular LA4
in neurons was found in a stable insoluble pool [47].
Moreover, the preponderant peptide of this pool is
LA41ÿ42. The fact that most of this peptide is gener-
ated in the ER/IC compartments in neurons where
also presenilins are localized [48], emphasizes the im-
portant role of this neuronal intracellular pool in AD
pathogenesis. Although the aggregation of intracellu-
lar amyloid peptide is also observed in non-neuronal
cells, the subcellular environment in neurons may
favor this process [47].
A third important factor to consider is the neuron
speci¢c character of APP tra⁄cking. Polarized neu-
rons such as hippocampal neurons are in essence
characterized by two domains, the axonal and soma-
todendritic domain, each with a distinct protein and
lipid composition [49,50]. In order to maintain this
morphological and functional polarization, selective
mechanisms must occur that transport proteins spe-
ci¢cally to one of the two domains [51^53]. Newly
expressed APP is ¢rst targeted to the axon where it is
exposed at the plasma membrane and subsequently
internalized [54] and sorted to a rab5 positive com-
partment devoid of synaptic vesicle components
[55,56]. Finally APP is delivered to the dendritic do-
main, potentially by a transcytotic mechanism
[57,58]. Some peripheral cell lines such as Madine^
Darby canine kidney (MDCK) cells, also have at
least two morphological and functional well-sepa-
rated plasma membrane domains, the apical and ba-
solateral domains corresponding to the axonal and
somatodendritic region in neurons, respectively, and
it is generally believed that analogous tra⁄cking
mechanism exist in both cell types to maintain this
polarity. Therefore, it came as a surprise that in
MDCK cells, APP is delivered basolaterally [59^
62]. Apical (mis)sorting in these cells was only ob-
served with the Swedish double mutation [60]. The
axonal versus basolateral sorting of APP in hippo-
campal neurons and MDCK cells respectively, ar-
gues again for a neuron speci¢c sorting and process-
ing component in APP metabolism.
4. Neuronal cell lines or primary cultures of neurons?
The choice of a particular cell culture system al-
ways depends on the type of question under inves-
tigation. There are no a priori’s in this regard. As
discussed above, for AD research, neurons are an
obvious choice for several reasons. However other
cell lines can be useful as well, and many important
aspects of APP and PS cell biology have been eluci-
dated in ¢broblasts and other non-neuronal cell lines.
When it comes to choose between neuronal cell lines,
like human NT2N, SH-SY5Y, murine neuro2A and
rat PC12, or rodent primary cultures of hippocampal
neurons or cortical neurons, several elements have to
be taken into account. Stable cell lines expressing
APP, PS1 or both have been successfully generated
[15], but ^ like PC12 and SH-SY5Y ^ these neuro-
blastoma cell lines only acquire some of the neuronal
phenotype upon di¡erentiation by growth factors
[63]. Furthermore, they do not develop into polarized
neurons making them unsuitable to study for in-
stance the relationship between polarized sorting
and APP metabolism. On the other hand, the partial
neuronal phenotype and the advantage that these cell
lines can be grown to large quantities, make them a
very useful tool for biochemical [64] and subcellular
fractionation studies [55,65].
NT2N cells are derived from Ntera 2, a human cell
line with characteristics that resemble CNS neuronal
precursor cells [66] after retinoic acid treatment. Sev-
eral steps are performed resulting after 3^4 weeks of
culture into a s 95% pure culture of postmitotic,
polarized human neurons [67]. The neurites of these
NT2N cells are at least partially di¡erentiated into
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axons and dendrites. The latter accumulate ribo-
somes, a functional feature of these dendrites. How-
ever, these neurons seem not to develop other speci-
alized properties, like synaptic contacts. In contrast,
primary cultures of rat and mouse hippocampal neu-
rons do develop such features (see below). Neverthe-
less, relatively large quantities of these neurons can
be obtained rendering them accessible to biochemical
experiments. In addition, NT2N cells continue to
express proteins after plasmid transfection of the un-
di¡erentiated NT2 cells [67], which allows the gener-
ation of stable transfected neuronal cell lines. The
relevance of this cell type with regard to the APP-
neuron speci¢c metabolism mentioned above is very
well documented. The retinoic acid treatment induc-
ing neuronal di¡erentiation also results in a shift
from predominantly APP751/APP770 (‘peripheral
APP’) in NT2 cells to almost exclusively APP695
(‘neuronal APP’) in NT2N cells, suggesting that
this form may well be the source of LA4 peptides
in AD [30]. The LA4 peptides are produced intra-
cellularly and rapidly released in the medium. This
secretion increases ¢ve-fold in the fully di¡erentiated
culture as compared to the undi¡erentiated cells,
pointing again to the importance of using neurons
for these type of studies [68].
An alternative neuronal model that meets many of
the above-mentioned criteria, is the primary culture
of rodent hippocampal neurons. These neurons are
prepared from hippocampi of 17- or 18-day embry-
onal rat or mice according to well established proce-
dures [69]. At this stage, pyramidal neurons are the
principal cell type of the embryonic hippocampus. As
most CNS cells, hippocampal neurons elaborate two
distinct classes of processes, axons and dendrites,
which di¡er in morphology, composition and func-
tion. The hippocampal neurons acquire this architec-
ture via a stereotypic sequence of ¢ve developmental
events [49,69]. At stage 1, cells are attached to the
poly-L-lysine substrate and develop short lamellipo-
dia, which ^ only a few hours later ^ already trans-
form into short processes (stage 2). From the mo-
ment one of these processes begins to grow at a
much faster rate, the axon is identi¢ed and the cell
becomes polarized (stage 3). This occurs already at
day 1.5 post-plating. After about 4 days in culture,
signi¢cant dendritic growth is observed from the re-
maining processes (stage 4). Finally, neuronal matu-
ration occurs, i.e. an increase in axonal density and
dendritic arborization, including branching and the
formation of synaptic boutons (stage 5) [70]. Full
maturation and long-term survival is achieved by
coculturing the neurons on a glia feeder layer.
Although in this ‘sandwich’ culture cells do not con-
tact each other, soluble neurotrophic factors can dif-
fuse between them to support neuronal survival and
development. As mentioned already, a major advant-
age that favors hippocampal neurons above polar-
ized human NT2N neurons is the fact that matura-
tion of hippocampal neurons is accompanied by the
establishment of functional synaptic contacts [70],
and dendritic spines. These dendritic protrusions
are implicated in synaptic plasticity and facilitate in-
duction of LTP [71^74], an important aspect when
studying neurodegenerative disorders like AD.
Equally interesting, presenilin function has been re-
cently linked to neuritic outgrowth and maturation
via its functional interaction with cell^cell contact
mediated Notch activation [75,76]. If Notch is
playing a role in the stability of neuronal networks,
it is likely that changes in Notch signaling may
imbalance neurites in neurodegenerative diseases,
such as AD. Therefore, neuronal models such as hip-
pocampal neurons developing functional synaptic
contacts that mimic the in vivo neuronal architec-
ture as much as possible will certainly be favored
in AD research or other neurodegenerative disor-
ders.
The only drawback is that mouse and rat do not
develop AD spontaneously. It could be argued there-
fore that molecular mechanisms inherent to abnor-
mal APP processing believed to cause AD are lack-
ing in rodentia. However, we could demonstrate that
simple ‘humanization’ of the amyloid region of APP
in these species is su⁄cient to initiate amyloid pro-
duction to levels indiscernible from those in human
cell types [77]. This indicates furthermore that the
three amino acid di¡erences in rodent APP com-
pared to human APP are su⁄cient to explain amy-
loid production in human brain. We can, at least,
conclude from these experiments that rodent neurons
contain the complete machinery, and, most impor-
tantly, the di¡erent secretases involved in the pro-
teolysis of APP and amyloidogenesis. Since mice
are still the preferred species to generate transgenic
or knock-out animals, many opportunities come with
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this type of culture to investigate APP metabolism in
neurons derived from interesting transgenic mice ex-
pressing modi¢ed genes implicated in the disease.
Two important prerequisites must be ful¢lled, how-
ever. First, in the case of ablation of genes, embryos
must be viable till embryonic day 14 (for cortical
neurons) and day 17 (for hippocampal neurons).
This approach has been successfully applied in the
past to rule out a role for cathepsin D as a candidate
secretase [78].
Second, in case of transgenics overexpressing cer-
tain wild-type or mutant proteins linked to AD, a
good promoter must be chosen. The promoter
should (1) drive expression of the transgene in neu-
rons, in (2) su⁄cient amounts to allow to distinguish
it from the endogenous protein and, most important,
(3) it must be activated in neuronal cultures in vitro.
Di¡erent neuron-speci¢c promoters have been
used for the expression of full-length human APP
in mice such as neuron-speci¢c enolase (NSE)
[8,79^81], promoter fragments from the gene encod-
ing synapsin I [82], the endogenous mouse APP pro-
moter [83], the promoter of Platelet-derived growth
factor B-chain (PDGF-B) [11], Thy-1 [19,80,84], or
the prion promoter [10]. Interestingly, Wirak et al.
identi¢ed a 4.5 kb DNA fragment from the 5P end of
the human APP gene, which mediates neuron- spe-
ci¢c gene expression in the CNS of transgenic mice,
and this promoter was subsequently used to control
expression of the LA4 peptide [85]. The Thy-1 pro-
moter is one of the favorite promoters now, since it
results in transgene APP protein expression levels
that match or even exceed the endogenous mouse
protein. Although these mice develop several inter-
esting features of the pathology associated with AD
[19,86], the Thy-1 promoter is not suitable for ex-
pression experiments in primary cultures of cortical
or hippocampal neurons because it is not active at
embryonal days 14^17 (our unpublished observa-
tions). Two other promoters, the PDGF-B and PrP
promoter, are more interesting in that regard. A
transgenic model in which the chloramphenicol ace-
tyltransferase gene was placed under the control of
the PDFG-B promoter revealed expression of the
enzyme preferentially in neurons as early as day
E15 [87]. Similar results have been obtained with
the PrP promoter using the lacZ gene as reporter
in the hamster prion gene cosmid vector cos.Tet
[88]. X-gal staining was observed at or before day
E7.5 (P. Tremblay,UCSF, California, personal com-
munication). This was con¢rmed by our own experi-
ence when using transgenic mice expressing human
wild-type and mutant PS1 under the control of the
PrP promoter [17]. Hippocampal neurons express the
human PS1 as early as day 3 post-plating as judged
from Western blotting using human speci¢c PS1 anti-
bodies [48,89].
5. The use of viral transfection in neuronal cultures
High-level expression of recombinant proteins in
non-dividing, postmitotic cells, such as NT2-N cells
and hippocampal neurons, by classic eukaryotic ex-
pression vectors is impeded by weak transfection ef-
¢ciency. Recombinant viruses are more e⁄cient of
which the baculoviral system is probably the best
in terms of protein production. However, the tech-
nique is labor-intensive and can only be used in in-
sect cells [90]. Instead, viral vectors based on RNA-
viruses (such as the alphaviruses Semliki forest virus
and Sindbis virus) and DNA-viruses such as adeno-
virus or herpes simplex virus (HSV) have been intro-
duced for heterologous protein production in non-
dividing cells. In hippocampal neurons, viral overex-
pression occurs in more than 50% of the neurons [91]
and generally does not a¡ect targeting and sorting of
the recombinant protein as was demonstrated by
comparison with the endogenous protein [51,92].
SFV expresses its genes more rapidly compared to
other viral vectors. For instance, protein expression
is observed already 1 h after infection and peaks at
6 h while in the case of adenovirus, protein expres-
sion is visible after 6 h with a maximum after 48^72
h [93]. Also HSV requires longer expression times
[94]. All viral vectors have cytopathogenic e¡ects,
which appear relatively late after transduction [95^
97]. The experimental time window from 4 h to at
least 24 h is therefore especially in favor for the
short-term expression of proteins using the SFV ex-
pression system.
Although Sindbis viral vector is constructed simi-
larly, the transfection e⁄ciency is much lower, sev-
eral passages (as compared to one overnight trans-
fection for SFV) are required to obtain su⁄ciently
high titers and, importantly, recombination may oc-
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cur [95,98]. Moreover, the SFV system improved
considerably since its original introduction [95]. In
order to minimize the chance to generate replication
pro¢cient virus, a mutation was introduced in the
gene encoding the spike protein p62 preventing it
from maturing [99]. Directional cloning was made
easier by insertion of an additional synthetic poly-
linker in the pSFV1 vector [100]. Most promising,
however, is the recent generation of a DNA-based
SFV-vector by adding the SV40 polyadenylation sig-
nal sequence downstream of the polylinker cassette
of pSFV3 and the RNA^polymerase II-dependent
cytomegalovirus immediate early enhancer/promoter
in front [101] or instead of the original SP6 promoter
Fig. 1. Schematic representation of our in vitro neuronal model of dissociated hippocampal neurons. In a ¢rst step, the hippocampi
are dissected out of the brains of murine brain expressing no (knock-out), human wild-type or mutant PS1 (asterisk). To generate
PS13/3 embryos, heterozygous PS1+/3 mice were used. In the other case, males heterozygous for human PS1 were crossed with
non-transgene females. In both cases, littermate embryos expressing endogenous PS1 are generated that serve as a control. Next, hip-
pocampal neurons are dissociated (about 1U106 cells/embryo) and cultured on plastic dishes or glass coverslips according to estab-
lished procedures [69]. Neurons can be maintained healthy up to 10 days after plating on plastic dishes and more than 3 weeks when
plated on glass coverslips in the presence of a glia feeder layer. This culture is exempli¢ed in the inset showing a fully polarized neu-
ron double immunostained for synaptobrevin II (green, mAb 69.1, gift of R. Jahn, Go«ttingen) and PS1 (red, pAb 17.2 [48]). At day 4
post-plating, neurons were infected for 1 h with SFV-APP constructs bearing no, a clinical (asterisk) or a sorting mutation followed
by a post-infection period of 2 h. In the case of metabolic studies, 35S-methionine is added to the culture medium and both medium
and cell lysates are collected after 4 h continuous labeling. Extracts were immunoprecipitated with the proper antibodies and the dif-
ferent APP-metabolites were analyzed by SDS^PAGE followed by phosphorimaging. Relative contribution of LA41ÿ40 and LA41ÿ42
was quanti¢ed by ELISA [113]. Alternatively, de¢cient sorting of APP can be analyzed in polarized neurons grown on glass coverslips
by confocal immuno£uorescence microscopy [48].
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[102]. This new vector yielded 20^30-fold more pro-
tein as compared to a classic expression vector and
was 10^20-fold more e⁄cient as compared to a sim-
ilar Sindbis virus-based plasmid [102]. In contrast to
the Sindbis virus, generation of replication pro¢cient
virus was never detected, so far providing an addi-
tional advantage for the SFV vector. Finally, Polo et
al. [114] recently developed stable cell lines for pack-
aging alphaviruses which can be used for the large-
scale vector production.
6. Achievements in AD research using neuronal
models
The SFV-system has been a successful neurobio-
logical tool (reviewed in [103]) for expression of li-
gand-gated ion channels [104], GABA receptors [105]
and the study of the polarized tra⁄cking of heterol-
ogous proteins in cultured neurons [51,70,91,106]. In
this regard, this system has been especially useful in
elucidating the metabolism and sorting of APP in
hippocampal neurons (see Fig. 1) as well as in
NT2N neurons. This approach was successful in
demonstrating that newly synthetized and glycosylat-
ed APP is sorted to axonal membranes where it can
be reinternalized and subsequently transcytosed to
the somatodendritic area [57]. Surprisingly, the LA4
region is a prerequisite for targeting APP to the axo-
nal compartment [107].
On its way, APP can be either cleaved by K-secre-
tase at or close to the plasma membrane, or by L-
secretase in the late secretory pathway. Amyloid pep-
tides are ¢nally generated by di¡erent Q-secretase ac-
tivities, preferentially in endocytic compartments
(LA41ÿ40) or in the ER (LA41ÿ42) (reviewed in [20]).
With respect to APP metabolism important break-
throughs have been made on identifying intracellular
and secreted pools of LA4 peptides and the site
where they are generated [36,40,108], as well as ef-
fects on LA4 production due to clinical mutations
[45,77], cholesterol depletion [109] and PS1 de¢ciency
[22,110]. Questions such as the lack of PS1 on the
sorting of unprocessed APP carboxyterminal stubs or
other target proteins sensitive to PS1 cleavage are
currently being addressed in the laboratory. At this
point, transgenic mice come into the picture again
and the application of the SFV-expression system
in hippocampal neurons derived from mice transgen-
ic for other AD-related proteins is an attractive pos-
sibility.
With respect to PS1 transgene expression, this ap-
proach is particularly interesting for the following
reasons: (1) PS1 is expressed in polarized neurons
that are more prone to the disease; (2) in contrast
to transfected non-neuronal cells, human PS1 is
mainly endoproteolysed in hippocampal neurons de-
rived from PS1-transgene mice (see [111]; (3) clinical
mutations (for instance M146L) do not virtually alter
the proteolytic processing and subcellular localiza-
tion of the mutant PS1 in neurons [15,89,111]; (4)
using the Semliki forest virus system APP (or other
AD-related proteins) can be e⁄ciently introduced to
study the e¡ect of single or double mutations provid-
ing a fast and reliable read-out and functional anal-
ysis. In the case of APP, not only AD-related muta-
tions, but also mutants de¢cient in critical sorting
steps (such as, for example, ER-retrieval, plasma
membrane internalization, axonal delivery) and their
e¡ect(s) on APP metabolism are within reach of the
cell biologist making it a superior in vitro model
system [48,57,64,107,112].
Fig. 1 gives a schematic £ow-chart of this in vitro
neuronal cell model as currently used on a routine
basis in our laboratory.
7. Conclusions
A picture is emerging that the presenilin-mediated
cleavage of APP is of pivotal importance in the
pathogenesis of AD and suggests Q-secretase as a
major therapeutic target in the disease. Therefore,
determining the amino acid residues in both proteins
required for this event will be useful for the develop-
ment of new drugs to treat the disease. This implies
the large scale testing of mutant APP or presenilin
bearing single point mutations or sorting defects that
all must be tested in relevant models. One of the
prerequisites for structure^function analysis of the
APP-presenilin-Q-secretase connection is to bring
these two proteins together, preferentially in a bio-
logical relevant system. Because of their hydrophobic
nature and presence in di¡erent subcellular compart-
ments, there is a great need for cellular models that
guarantee a fast and reliable read-out.
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